Struggling GlobeImmune brings in financial advisers as options dwindle

Not long after a mid-stage trial failure blasted its stock value and forced the company to lay off most of its staff, a troubled GlobeImmune ($GBIM) has brought in Cantor Fitzgerald to advise the biotech on its "strategic options"--which may signal that a fire sale is in the offing.

GlobeImmune CEO Timothy Rodell

GlobeImmune CEO Timothy Rodell had tried to make the best of things when he fingered signs of biologic activity among a handful of patients given the hep B vaccine GS-4774 in a Phase II trial. But the big takeaway was that the Louisville, CO-based company's lead program had flunked out when given a chance to establish proof-of-concept data among the 178 patients in the study.

As a result of that failure, GlobeImmune's shares were shattered and the company's market cap sits at a tiny $15 million--a bite-sized target for anyone interested in the company.

Gilead in-licensed the hep B program back in 2011 and the biotech has a second Phase II trial underway as well. Celgene ($CELG), meanwhile, stepped in early a few days ago to pick up its option on GI-6207, which targets cancer cells that express a carcinoembryonic antigen.

Celgene paid only $1.9 million for the accelerated option, with potential royalties attached, gaining a therapy that's now in a 34-patient Phase II study at the NCI, where investigators are studying its impact on calcitonin levels--a biomarker for recurrent medullary thyroid cancer.

The biotech industry has enjoyed a three-year romp on Wall Street, but weak companies with small pipelines are at risk of a savage beating at the hands of investors when things go sour. GlobeImmune only raised about $15 million when it sold a batch of IPO shares at $10 each--well under its range--last summer. The stock was trading at $2.60 this morning.

- here's the release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.

The series A gives ex-Roche VP George Garibaldi a chance to realize the potential of assets that fell by the wayside at the Swiss pharma.